Non-Small Cell Lung Cancer Archives - Page 74 of 83

Mutational events that lead to MET exon 14 skipping may be targetable events in pulmonary sarcomatoi

Lung Cancer

Frequent, Actionable MET Gene Mutations Found in Pulmonary Sarcomatoid Carcinoma

By

Stephen Cho

July 28, 2015

Mutational events that lead to MET exon 14 skipping may be targetable events in pulmonary sarcomatoid carcinoma (PSC).

KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib in NSCLC.

Lung Cancer

KRAS Not Prognostic, Predictive of Docetaxel or Erlotinib Benefit

By

Jason Hoffman, PharmD, RPh

July 24, 2015

KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib in non-small cell lung cancer (NSCLC).

Four regions in the human genome linked to pancreatic cancer risk have been identified.

Lung Cancer

MIRLET7BHG Polymorphisms Associated with Asbestos-related Lung Cancer

July 24, 2015

Interaction between single nucleotide polymorphisms (SNPs) and asbestos exposure correlated to increased lung cancer risk in MIRLET7BHG carriers

Lung Cancer

Greatest EGFR Prevalence in Women with Adenocarcinoma with No Smoking History

July 24, 2015

Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations.

Higher drug doses according to lean body mass may be a significant predictor of toxicity in NSCLC.

Lung Cancer

Dosage by Lean Body Mass May Lower Toxicity in Lung Cancer

By

Stephen Cho

July 21, 2015

Higher drug doses according to lean body mass may be a significant predictor of toxicity in non-small cell lung cancer (NSCLC).

Options for treatment of patients with non-squamous NSCLC who progress after initial therapy are lim

Lung Cancer

Tivantinib Plus Erlotinib Improves Progression-Free, Not Overall Survival in Lung Cancer

By

Jason Hoffman, PharmD, RPh

July 14, 2015

Erlotinib plus tivantinib was well tolerated and increased PFS but did not improve OS in non-small cell lung cancer (NSCLC).

Lung Cancer

FDA Approves Gefitinib As First-Line Treatment for EGFR+ Lung Cancer

By

Jason Hoffman, PharmD, RPh

July 13, 2015

The FDA has approved Iressa (gefitinib) for the first-line treatment of mutation-positive non-small cell lung cancer (NSCLC).

Lung Cancer

Positive Results Observed in Family Caregivers of Patients with Lung Cancer After Interventions

July 10, 2015

Family caregivers who received interdisciplinary palliative care intervention reported greater social well-being and less psychological distress.

Prophylactic Cranial Irradiation Doesn't Prolong OS in Extensive Disease-SCLC

Lung Cancer

Platinum-Based Doublet Chemo Remains Standard of Care after First-Line Gefitinib

By

Jason Hoffman, PharmD, RPh

July 9, 2015

Continuation of gefitinib after progression on first-line gefitinib did not improve survival in non-small cell lung cancer (NSCLC).

Lung Cancer

Tivantinib Plus Erlotinib May Improve Survival in Non-Squamous Lung Cancer

By

Jason Hoffman, PharmD, RPh

July 9, 2015

Tivantinib plus erlotinib might improve progression-free survival in non-squamous non-small cell lung cancer (NSCLC).

Diagnosis & Disease Information

Frequent, Actionable MET Gene Mutations Found in Pulmonary Sarcomatoid Carcinoma

KRAS Not Prognostic, Predictive of Docetaxel or Erlotinib Benefit

MIRLET7BHG Polymorphisms Associated with Asbestos-related Lung Cancer

Greatest EGFR Prevalence in Women with Adenocarcinoma with No Smoking History

Dosage by Lean Body Mass May Lower Toxicity in Lung Cancer

Tivantinib Plus Erlotinib Improves Progression-Free, Not Overall Survival in Lung Cancer

FDA Approves Gefitinib As First-Line Treatment for EGFR+ Lung Cancer

Positive Results Observed in Family Caregivers of Patients with Lung Cancer After Interventions

Platinum-Based Doublet Chemo Remains Standard of Care after First-Line Gefitinib

Tivantinib Plus Erlotinib May Improve Survival in Non-Squamous Lung Cancer

Concurrent Chemoradiotherapy Should Remain Standard of Care for Locally Advanced NSCLC